{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:04:39Z","timestamp":1790679879790,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Early Human Development"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.earlhumdev.2011.01.014","type":"journal-article","created":{"date-parts":[[2011,2,2]],"date-time":"2011-02-02T04:45:17Z","timestamp":1296621917000},"page":"S61-S65","source":"Crossref","is-referenced-by-count":22,"special_numbering":"S","title":["Pharmacokinetics of antifungal agents in children"],"prefix":"10.1016","volume":"87","author":[{"given":"Kevin","family":"Watt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Daniel K.","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.earlhumdev.2011.01.014_bb0005","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.42.4.734","article-title":"Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center","volume":"42","author":"Boschman","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.earlhumdev.2011.01.014_bb0010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/SLA.0b013e31819ed914","article-title":"The epidemiology of Candida colonization and invasive candidiasis in a surgical intensive care unit where fluconazole prophylaxis is utilized: follow-up to a randomized clinical trial","volume":"249","author":"Magill","year":"2009","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.earlhumdev.2011.01.014_bb0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0002-9343(95)00010-0","article-title":"The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance","volume":"100","author":"Nguyen","year":"1996","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.earlhumdev.2011.01.014_bb0020","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/423378","article-title":"A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis","volume":"39","author":"Krause","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"9495","key":"10.1016\/j.earlhumdev.2011.01.014_bb0025","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.earlhumdev.2011.01.014_bb0030","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.earlhumdev.2011.01.014_bb0035","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.earlhumdev.2011.01.014_bb0040","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.earlhumdev.2011.01.014_bb0045","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/374850","article-title":"A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects","volume":"36","author":"Rex","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.earlhumdev.2011.01.014_bb0050","first-page":"95","article-title":"Amphotericin B serum levels in pediatric bone marrow transplant recipients","volume":"7","author":"Emminger","year":"1991","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.earlhumdev.2011.01.014_bb0055","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0022-3476(05)82674-5","article-title":"Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates","volume":"116","author":"Baley","year":"1990","journal-title":"J Pediatr"},{"issue":"11","key":"10.1016\/j.earlhumdev.2011.01.014_bb0060","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1128\/AAC.33.11.1989","article-title":"Pharmacokinetics of amphotericin B in children","volume":"33","author":"Benson","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.01.014_bb0065","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0022-3476(88)80653-X","article-title":"Pharmacokinetics and adverse effects of amphotericin B in infants and children","volume":"113","author":"Koren","year":"1988","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.earlhumdev.2011.01.014_bb0070","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/infdis\/155.4.766","article-title":"Pharmacokinetics of amphotericin B in infants and children","volume":"155","author":"Starke","year":"1987","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.earlhumdev.2011.01.014_bb0075","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.0306-5251.2001.01496.x","article-title":"Population pharmacokinetics of amphotericin B in children with malignant diseases","volume":"52","author":"Nath","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0080","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0030-6665(00)80005-5","article-title":"Agents for treatment of invasive fungal infections","volume":"33","author":"Luna","year":"2000","journal-title":"Otolaryngol Clin North Am"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0085","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1128\/AAC.35.1.188","article-title":"Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves","volume":"35","author":"Ralph","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.earlhumdev.2011.01.014_bb0090","doi-asserted-by":"crossref","first-page":"5092","DOI":"10.1128\/AAC.49.12.5092-5098.2005","article-title":"Population pharmacokinetics of amphotericin B lipid complex in neonates","volume":"49","author":"Wurthwein","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.01.014_bb0095","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.50.3.935-942.2006","article-title":"Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases","volume":"50","author":"Hong","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"1\u20132","key":"10.1016\/j.earlhumdev.2011.01.014_bb0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0378-5173(02)00066-2","article-title":"A comparative study of plasma concentrations of liposomal amphotericin B (L-AMP-LRC-1) in adults, children and neonates","volume":"238","author":"Kotwani","year":"2002","journal-title":"Int J Pharm"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0105","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerate dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.01.014_bb0110","doi-asserted-by":"crossref","first-page":"319","DOI":"10.7326\/0003-4819-86-3-319","article-title":"Flucytosine","volume":"86","author":"Bennet","year":"1977","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.earlhumdev.2011.01.014_bb0115","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1001\/archderm.109.6.873","article-title":"Flucytosine. An effective oral treatment for chromomycosis","volume":"109","author":"Mauceri","year":"1974","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0120","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/clinids\/12.6.1147","article-title":"Antifungal and surgical treatment of invasive aspergillosis: review of 2, 121 published cases","volume":"12","author":"Denning","year":"1990","journal-title":"Rev Infect Dis"},{"issue":"2","key":"10.1016\/j.earlhumdev.2011.01.014_bb0125","first-page":"170","article-title":"Hepatotoxicity of antifungal agents","volume":"6","author":"Song","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.earlhumdev.2011.01.014_bb0130","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0002-9343(87)90691-7","article-title":"Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis","volume":"83","author":"Stamm","year":"1987","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.earlhumdev.2011.01.014_bb0135","first-page":"424","article-title":"Clinical use of systemic antifungal agents","volume":"7","author":"Benson","year":"1988","journal-title":"Clin Pharm"},{"issue":"12","key":"10.1016\/j.earlhumdev.2011.01.014_bb0140","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.4065\/73.12.1205","article-title":"Antifungal agents. Part I. Amphotericin B preparations and flucytosine","volume":"73","author":"Patel","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0145","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1542\/peds.2004-2292","article-title":"Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months","volume":"117","author":"Benjamin","year":"2006","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.earlhumdev.2011.01.014_bb0150","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/clinids\/23.5.964","article-title":"Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature","volume":"23","author":"Anaissie","year":"1996","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.earlhumdev.2011.01.014_bb0155","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/00006454-199702000-00005","article-title":"Prevalence of Candida species in hospital-acquired urinary tract infections in a neonatal intensive care unit","volume":"16","author":"Phillips","year":"1997","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.01.014_bb0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2165\/00003088-199733010-00005","article-title":"Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses","volume":"33","author":"Debruyne","year":"1997","journal-title":"Clin Pharmacokinet"},{"issue":"7\u20138","key":"10.1016\/j.earlhumdev.2011.01.014_bb0165","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1439-0507.1997.tb00230.x","article-title":"Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility","volume":"40","author":"Wildfeuer","year":"1997","journal-title":"Mycoses"},{"issue":"4","key":"10.1016\/j.earlhumdev.2011.01.014_bb0170","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF01974613","article-title":"Pharmacokinetics of fluconazole in pediatric patients","volume":"13","author":"Brammer","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0175","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2165\/00003088-199733010-00005","article-title":"Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses","volume":"33","author":"Debruyne","year":"1997","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"10.1016\/j.earlhumdev.2011.01.014_bb0180","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/AAC.00569-08","article-title":"Population pharmacokinetics of fluconazole in young infants","volume":"52","author":"Wade","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0185","series-title":"Society for Pediatric Research Conference, Vancouver, Canada, May 2010","article-title":"Fluconazole Loading Dose Pharmacokinetics and Safety in Infants","author":"Piper","year":"2010"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0190","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1345\/aph.19237","article-title":"Voriconazole: a new triazole antifungal","volume":"34","author":"Sabo","year":"2000","journal-title":"Ann Pharmacother"},{"issue":"Suppl 2","key":"10.1016\/j.earlhumdev.2011.01.014_bb0195","first-page":"81","article-title":"In vitro susceptibility of itraconazole-resistant isolates of Aspergillus fumigatus to voriconazole","volume":"3","author":"Manavathu","year":"1997","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0200","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/42.6.741","article-title":"In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi","volume":"42","author":"Johnson","year":"1998","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.earlhumdev.2011.01.014_bb0205","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.earlhumdev.2011.01.014_bb0210","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2125.2003.01993.x","article-title":"Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0215","series-title":"UK-109496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man [abstract F78]","year":"1995"},{"issue":"5","key":"10.1016\/j.earlhumdev.2011.01.014_bb0220","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijantimicag.2009.12.021","article-title":"Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study","volume":"42","author":"Myrianthefs","year":"2010","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.earlhumdev.2011.01.014_bb0225","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/0091270002424005","article-title":"Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study","volume":"42","author":"Lazarus","year":"2002","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.earlhumdev.2011.01.014_bb0230","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.earlhumdev.2011.01.014_bb0235","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.clpt.2004.02.002","article-title":"Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status","volume":"75","author":"Ikeda","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.earlhumdev.2011.01.014_bb0240","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.01.014_bb0245","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.00751-08","article-title":"Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies","volume":"53","author":"Karlsson","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.earlhumdev.2011.01.014_bb0250","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1086\/424662","article-title":"Adverse reactions to voriconazole","volume":"39","author":"Boyd","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.earlhumdev.2011.01.014_bb0255","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1086\/324620","article-title":"Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis","volume":"34","author":"Denning","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"45\u201346","key":"10.1016\/j.earlhumdev.2011.01.014_bb0260","first-page":"739","article-title":"Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring","volume":"136","author":"Imhof","year":"2006","journal-title":"Swiss Med Wkly"},{"issue":"4","key":"10.1016\/j.earlhumdev.2011.01.014_bb0265","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.earlhumdev.2011.01.014_bb0270","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","article-title":"Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients","volume":"109","author":"Trifilio","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.earlhumdev.2011.01.014_bb0275","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/adc.2007.118844","article-title":"Voriconazole plasma monitoring","volume":"93","author":"Pasqualotto","year":"2008","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.01.014_bb0280","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.earlhumdev.2011.01.014_bb0285","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1592\/phco.2005.25.6.893","article-title":"Intravenous voriconazole therapy in a preterm infant","volume":"25","author":"Muldrew","year":"2005","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.earlhumdev.2011.01.014_bb0290","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.inf.0000258698.98370.89","article-title":"Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin","volume":"26","author":"Santos","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.earlhumdev.2011.01.014_bb0295","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/01.inf.0000095167.38306.76","article-title":"Voriconazole serum concentrations in an infant treated for Trichosporon beigelii infection","volume":"22","author":"Maples","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"9","key":"10.1016\/j.earlhumdev.2011.01.014_bb0300","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.earlhumdev.2011.01.014_bb0305","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1128\/AAC.45.12.3322-3327.2001","article-title":"Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits","volume":"45","author":"Groll","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0310","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/AAC.44.2.441-443.2000","article-title":"In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B","volume":"44","author":"Moore","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0315","first-page":"555","article-title":"Ravuconazole","volume":"3","author":"Arikan","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0320","series-title":"Ravuconazole single ascending oral dose study in healthy subjects","year":"2000"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0325","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000048580","article-title":"Penetration of ravuconazole, a new triazole antifungal, into rat tissues","volume":"48","author":"Mikamo","year":"2002","journal-title":"Chemotherapy"},{"issue":"2","key":"10.1016\/j.earlhumdev.2011.01.014_bb0330","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3476(88)80069-6","article-title":"A randomized, controlled trial of parenteral clindamycin in neonatal necrotizing enterocolitis","volume":"112","author":"Faix","year":"1988","journal-title":"J Pediatr"},{"issue":"8 Pt 2","key":"10.1016\/j.earlhumdev.2011.01.014_bb0335","doi-asserted-by":"crossref","first-page":"165S","DOI":"10.1592\/phco.21.12.165S.34509","article-title":"Investigational antifungal agents","volume":"21","author":"Ernst","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.earlhumdev.2011.01.014_bb0340","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/mmy.38.s1.335.347","article-title":"New targets and delivery systems for antifungal therapy","volume":"38","author":"Walsh","year":"2000","journal-title":"Med Mycol"},{"issue":"8 Pt 2","key":"10.1016\/j.earlhumdev.2011.01.014_bb0345","doi-asserted-by":"crossref","first-page":"133S","DOI":"10.1592\/phco.21.12.133S.34507","article-title":"Antifungal pharmacodynamics: concentration\u2013effect relationships in vitro and in vivo","volume":"21","author":"Groll","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0350","unstructured":"Merck. Caspofungin Product Label. In: Administration FaD, editor.2010."},{"issue":"Suppl 1","key":"10.1016\/j.earlhumdev.2011.01.014_bb0355","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1439-0507.2008.01523.x","article-title":"Antifungal agents\u2014clinical pharmacokinetics and drug interactions","volume":"51","author":"Lipp","year":"2008","journal-title":"Mycoses"},{"issue":"4","key":"10.1016\/j.earlhumdev.2011.01.014_bb0360","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1128\/AAC.01027-08","article-title":"Pharmacokinetics and safety of caspofungin in older infants and toddlers","volume":"53","author":"Neely","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.earlhumdev.2011.01.014_bb0365","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1128\/AAC.00868-08","article-title":"Pharmacokinetics and safety of caspofungin in neonates and infants less than 3months of age","volume":"53","author":"Saez-Llorens","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.earlhumdev.2011.01.014_bb0370","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1128\/AAC.49.8.3317-3324.2005","article-title":"Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients","volume":"49","author":"Seibel","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.earlhumdev.2011.01.014_bb0375","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1248\/bpb.29.1706","article-title":"Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections","volume":"29","author":"Tabata","year":"2006","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.01.014_bb0380","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1086\/524063","article-title":"The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates","volume":"197","author":"Hope","year":"2008","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.earlhumdev.2011.01.014_bb0385","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/01.inf.0000245103.07614.e1","article-title":"The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants","volume":"25","author":"Heresi","year":"2006","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"10.1016\/j.earlhumdev.2011.01.014_bb0390","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/INF.0b013e3181910e2d","article-title":"Pharmacokinetics of an elevated dosage of micafungin in premature neonates","volume":"28","author":"Smith","year":"2009","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.01.014_bb0395","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.bmt.1705398","article-title":"A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation","volume":"38","author":"Sirohi","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.earlhumdev.2011.01.014_bb0400","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1128\/AAC.01596-07","article-title":"Pharmacokinetics and tissue distribution of anidulafungin in rats","volume":"52","author":"Damle","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.earlhumdev.2011.01.014_bb0405","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/0091270004265644","article-title":"Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal","volume":"44","author":"Dowell","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.earlhumdev.2011.01.014_bb0410","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1592\/phco.29.1.17","article-title":"Pharmacology and antifungal properties of anidulafungin, a new echinocandin","volume":"29","author":"Estes","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.earlhumdev.2011.01.014_bb0415","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/AAC.50.2.632-638.2006","article-title":"Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections","volume":"50","author":"Benjamin","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.earlhumdev.2011.01.014_bb0420","series-title":"Abstract: Safety and Pharmacokinetics (PK) of Multiple-Dose Anidulafungin in Neonates","year":"2010"}],"container-title":["Early Human Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378378211000247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378378211000247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T04:36:28Z","timestamp":1559968588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378378211000247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":84,"alternative-id":["S0378378211000247"],"URL":"https:\/\/doi.org\/10.1016\/j.earlhumdev.2011.01.014","relation":{},"ISSN":["0378-3782"],"issn-type":[{"value":"0378-3782","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}